Theodore Laetsch
Co-Leader, Pediatric Oncology Program, Abramson Cancer Center, University of Pennsylvania · Children's Hospital of Philadelphia
Credentials: · · · ·
History
- Present
Pediatric Oncology Program · Children's Hospital of Philadelphia
- Present
Division of Genomic Diagnostics Chief Search Committee · Children's Hospital of Philadelphia
- Present
Vice Chair · Children's Hospital of Philadelphia
Research
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
New England Journal of Medicine · 2018 · 4,577 citations
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
New England Journal of Medicine · 2018 · 2,193 citations
The Lancet Oncology · 2020 · 835 citations
21 papers
21 papers
19 papers
18 papers
- HP
17 papers
- KC
17 papers
17 papers
- HS
16 papers
Grants
- 2025–2030
Rare Tumor Clinical Research Specialist
National Cancer Institute · R50
Contact PI · $395K · Children's Hosp of Philadelphia
- 2026–2029
PROMISE — Pediatric Rare-Tumor Observational MultI-Source Evidence Network
Food and Drug Administration · U01
PI · $1.5M · Children's Hosp of Philadelphia
- 2015–2022
Image-Guided Doxorubicin Delivery for Pediatric Sarcomas
National Cancer Institute · R01
PI · $2.8M · Ut Southwestern Medical Center
Clinical trials
- 2024–2031
Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)
Principal investigator · Recruiting · Phase 2
Children's Hospital of Philadelphia
- 2024–2027
Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer
Principal investigator · Recruiting · Phase 2
Children's Hospital of Philadelphia
- 2023–2028
Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas
Principal investigator · Recruiting · Phase 1
Children's Hospital of Philadelphia
- 2023–2029
Lurbinectedin in FET-Fused Tumors
Principal investigator · Recruiting · Phase 1, Phase 2
Children's Hospital of Philadelphia